Medical Services Group HC Surgical Specialists Launches Initial Public Offer at S$0.27 Per Share
- Dedicated to making high quality private healthcare accessible to the broadest consumer base possible - Intends to distribute at least 70% of profit after tax as dividends for FY2017, FY2018 and FY2019 - Placement of 30,000,000 Placement Shares at S$0.27 each
SINGAPORE, Oct 25, 2016 - (ACN Newswire) - HC Surgical Specialists Limited ("HCSS" and together with its subsidiaries, the "Group"), a medical services group primarily engaged in the provision of endoscopic procedures, including gastroscopies and colonoscopies, and general surgery services with a focus on colorectal procedures, has launched its Initial Public Offering ("IPO") in conjunction with its proposed listing on the Catalist board ("Catalist") of the Singapore Exchange Securities Trading Limited ("SGX-ST").
Led by specialist surgeons, Dr. Heah Sieu Min (Chief Executive Officer) and Dr. Chia Kok Hoong (Chief Operating Officer), and supported by a team of experienced specialist surgeons and general practitioners, HCSS operates a network of clinics throughout Singapore. Its clinics are located across central Singapore in certain private hospitals and in residential areas, including the heartlands, and are close to public transportation. Its specialist surgeons also operate evening clinics, which enhances the Group's accessibility to patients at any time of the day. Common conditions treated by the Group include haemorrhoids, gallstones and inflammation of the gallbladder, hernias, colorectal cancer, stomach cancer and colonic diverticular disease.
The Group's clinics offer an extensive range of endoscopy and general surgical procedures. Most of its clinics are fully equipped to provide a comprehensive suite of diagnostic and therapeutic endoscopic procedures, excision of lumps and removal of polyps, as well as other minor surgical services on site. The centres are Medisave accredited ie medisave funds may be used to offset procedure costs and Medishield Insurance coverage may apply as well.
Dr. Heah and Dr. Chia collectively have over 40 years of experience, and both have received several awards and accreditations throughout their careers. Their active involvement in the day-to-day operations of the clinics enables the Group to increase its responsiveness to its patients. Each of the Group's other specialist surgeons also have extensive track records.
To reward shareholders for participating in the Group's growth, HCSS intends to pay out at least 70.0% of its profit after tax as dividends for FY2017, FY2018 and FY2019.
Prospects and Future Plans
The rising affluence in Singapore increases the affordability of private healthcare services. Higher educational standards may also increase the awareness of, and drive the demand for, high quality and comprehensive medical services. With an ageing population in Singapore, there could be a corresponding increase in the incidence of certain diseases such as colorectal cancer, which may translate into a greater demand for medical services. The ageing population has also led to changes being made to the national insurance scheme, including an increase in the coverage age under MediShield. In addition, increasing healthcare costs and greater interest in healthcare services has led to a growing demand for private healthcare insurance. As a result, Singaporeans are becoming more well-insured, which could increase their willingness to seek out private healthcare services.
Besides diversifying its patient base to include more corporate clients, the Group plans to expand its business locally through organic growth, entering into joint ventures or through acquisitions of other clinics, surgical specialists and general practitioners. It also intends to extend its capabilities by setting up day surgery centres equipped with surgical facilities for, among others, general surgery, orthopaedics, dental services and aesthetic procedures.
On the regional front, HCSS plans to bring its medical services into Vietnam. It has entered into a non-binding memorandum of understanding with the Transport Hospital in Hanoi, Vietnam, to provide consultancy and training services. The Group will also assist the Transport Hospital in establishing a day surgery and endoscopy centre, where its specialist surgeons will have exclusive rights to perform surgical and endoscopic procedures.
Dr. Heah said, "The Group will continue to expand our network of clinics and extend our capabilities, in line with our vision to develop an organisation dedicated to reaching out to the broadest consumer base possible. Most of our specialist clinics are equipped to perform endoscopy and minor surgical procedures safely, seamlessly and with a reduced waiting time, thereby adding convenience for patients. We intend to continue contributing to our nation by making high quality, affordable healthcare accessible to our growing population."
The Placement
30,000,000 new shares are being offered (the "Placement Shares") for subscription by way of placement at the issue price of S$0.27 per share (the "Issue Price"). The Placement Shares, upon issue and allotment, will rank pari passu in all respects with the existing issued shares of the Company.
Trading in the Company's shares on Catalist is expected to commence at 9.00 a.m. on 3 November 2016.
Use of Proceeds
The net proceeds raised of approximately S$6.15 million will be used for the following purposes: - S$2.80 million (45%) for the expansion of the Group's business operations locally and regionally; - S$1.20 million (20%) for the expansion of the Group's surgical facilities; and - S$2.15 million (35%) for general working capital purposes
Issued on behalf of HC Surgical Specialists Limited by:
Waterbrooks Consultants Pte Ltd Tel: +65 6100 2228 Lynette Tan (M): +65 9687 2023 lynette@waterbrooks.com.sg Ma Kin Hoong (M): +65 9384 0073 ma@waterbrooks.com.sg
Source: HC Surgical Specialists Limited Sectors: Daily Finance, Daily News
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
Mitsubishi Power Begins Commercial Operation of Seventh M701JAC Gas Turbine in Thailand GTCC Project; Achieves 75,000 AOH To-Date Apr 24, 2024 17:19 JST
| MC and Denka Sign J/V Agreement in Fullerene Business Apr 24, 2024 17:02 JST
| Mitsubishi Motors Posts Record Sales in the Philippines in FY2023 Apr 24, 2024 13:56 JST
| NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance Apr 24, 2024 13:25 JST
| Fujitsu SX Survey reveals key success factors for sustainability Apr 23, 2024 10:25 JST
| Fujitsu and METRON collaborate to drive ESG success: slashing energy costs, boosting productivity with new manufacturing industry solutions Apr 22, 2024 16:09 JST
| NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II Apr 22, 2024 15:09 JST
| Soft Space Launches the First and Only JCB Payment Gateway in Malaysia Apr 22, 2024 15:00 JST
| TOYOTA GAZOO Racing takes a one-two in Croatian thriller Apr 22, 2024 10:47 JST
| First-ever Mazda CX-80 Crossover SUV Unveiled in Europe Apr 19, 2024 13:50 JST
| Fujitsu develops technology to convert corporate digital identity credentials, enabling participation of non-European companies in European data spaces Apr 19, 2024 10:17 JST
| Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas Apr 18, 2024 17:01 JST
| Toyota Launches All-New Land Cruiser "250" Series in Japan Apr 18, 2024 13:39 JST
| Fujitsu and Oracle collaborate to deliver sovereign cloud and AI capabilities in Japan Apr 18, 2024 11:14 JST
| Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) Apr 18, 2024 10:53 JST
| All-New Triton Confirmed as First Double-Cab Pickup Truck to Achieve 2024 Five-Star ANCAP Safety Rating Apr 18, 2024 09:22 JST
| Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan Apr 17, 2024 16:17 JST
| Honda Unveils Next-generation EV Series for China Apr 17, 2024 12:15 JST
| Lexus presents Time at the 2024 Milan Design Week Apr 16, 2024 18:49 JST
| Mitsubishi Corporation Announces Participation in a DAC Project in Louisiana, USA Apr 16, 2024 14:36 JST
|
More Latest Release >>
|